Additionally, NCOA2 is amplified or overexpressed in 8% of the primary pancreatic cancers, and its expression level is associated with tumor relapse following androgen deprivation therapy (ADT); mechanistically, NCOA2 overexpression in prostate tumors may lead to hyperactivation of the PI3K/AKT signaling, thus exacerbating tumor malignance (20). Here, NCOA2 is linked to familial pancreatic carcinoma.